Drug Discovery Image Professor Neil Carragher - Professor of Drug Discovery Research in a Nutshell The Edinburgh Drug Discovery group embraces advanced technology platforms and disease models, which drive innovations in oncology drug discovery and development. Our group is highly proficient in image-based phenotypic screening working in close collaboration with several pharmaceutical industry partners and academic groups to identify hit molecules, advance small-molecule lead generation and classify compound mechanism of action (MOA). Our laboratories are equipped with the latest kinetic (IncuCyte s3®) and high-content (ImageXpress-micoXLS, ImageXpress-confocal HT.ai and fast light-sheet oblique plane microscopy) screening platforms, fully integrated with plate-handling robotics, barcode sample tracking, image analysis and artificial intelligence/machine learning (AI/ML) workflows. We are founding members of the European Cell-Based Assay Interest group (http://www.eucai.org), and together with the Universities of Oxford and Dundee, we are the third major academic hub for the National Phenotypic Screening Centre (http://npsc.ac.uk/). We also incorporate Reverse Phase Protein Array (RPPA) and NanoString analysis to support biomarker discovery and drug MOA studies at the transcriptomic and post-translational pathway levels.The overarching aims of our group are to enhance clinical predictivity of preclinical oncology drug discovery and improve patient stratification and efficacy, by applying an evidence-led translational research platform, incorporating disease relevant models, innovative chemical design, quantitative imaging, genomic/proteomic-discovery-informatics and AI/ML tools. To achieve these goals we work in close collaboration with local clinicians, multidisciplinary academic research groups and industry partners. Research Programme Image People Neil CarragherPrincipal Investigator, Professor of Drug Discovery and Director of Edinburgh Cancer Discovery UnitJohn DawsonDeputy Leader of Phenotypic ScreeningRichard ElliottHead of High-throughput ScreeningAlison MunroLaboratory Manager (HTPU Microarray Services)Jayne CulleyResearch AssistantMartin LeeImaging Engineer (joint with Val Brunton)Alex LoftusPost Doc (joint with Margaret Frame)Mitch FosterECAT FellowBecka HughesPost DocMungo HarveyPhD StudentVanessa Smer-BarretoXDF FellowNhan PhamSenior Drug Screening Scientist (joint with Siddharthan Chandran)Rod CarterResearch Scientist (joint with Siddharthan Chandran)Steve ShaveResearch FellowContactPA : jan.irvine@ed.ac.uk Neil Carragher - Research Information CollaborationsAstraZenecaRadius Health Inc.Carrick TherapeuticsEli LillyJanssenNational Phenotypic Screening Centre: www.npsc.orgEuropean Cell-based Assay Interest group: www.eucai.orgGlobal RPPA society: http://capmm.gmu.edu/2015-rppa-globalworkshop-homeAsier Unciti-Broceta: Innovative Therapeutics GroupSteve Pollard Group Margaret Frame: Cancer Biology GroupVal Brunton: Cancer Therapeutics GroupPartners and FundersAstraZenecaRadius Health Inc.Carrick therapeuticsEli LillyJanssenEPSRC Research Grant (2016) (Unciti-Broceta, Patton, Leung, Carragher) Palladium-activated prodrug therapy: a novel focal therapy for localised cancers of unmet need (5YR): £1,074,212Wellcome Trust ISSF (Jan 2016 –Jan 2017) (Von-Kriegsheim, Carragher and Wills). Drug target deconvolution platform. (1YR): £54,368 + in-kind coallboration with MedimmuneBrain Tumour Charity Quest for Cures award (2016) (Pollard Dirks, Brennan, Helin and Carragher). Chromatin proteins as drug targets for glioblastoma. Research funding (5YR): £1,481,356Mechanistically informed Phenotypic Screening to Advance New Therapeutic Treatments for Oesophageal Cancer Patients £104,483Scientific ThemesDrug Discovery, Phenotypic Screening, Glioma, Esophageal cancer, breast cancerTechnology ExpertiseHigh content imaging, image-analysis, image-informatics, Reverse phase protein array This article was published on 2024-09-23
